| pubmed-article:16932348 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C0023470 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C0007589 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C1326205 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C0013081 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C1336767 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C0237477 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C0181586 | lld:lifeskim |
| pubmed-article:16932348 | lifeskim:mentions | umls-concept:C1511938 | lld:lifeskim |
| pubmed-article:16932348 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:16932348 | pubmed:dateCreated | 2006-10-16 | lld:pubmed |
| pubmed-article:16932348 | pubmed:abstractText | Among the topoisomerase (topo) II isozymes (alpha and beta), topo IIbeta has been suggested to regulate differentiation. In this study, we examined the role of topo IIbeta in all-trans retinoic acid (ATRA)-induced differentiation of myeloid leukemia cell lines. Inhibition of topo IIbeta activity or downregulation of protein expression enhanced ATRA-induced differentiation/growth arrest and apoptosis. ATRA-induced apoptosis in topo IIbeta-deficient cells involved activation of the caspase cascade and was rescued by ectopic expression of topo IIbeta. Gene expression profiling led to the identification of peroxiredoxin 2 (PRDX2) as a candidate gene that was downregulated in topo IIbeta-deficient cells. Reduced expression of PRDX2 validated at the mRNA and protein level, in topo IIbeta-deficient cells correlated with increased accumulation of reactive oxygen species (ROS) following ATRA-induced differentiation. Overexpression of PRDX2 in topo IIbeta-deficient cells led to reduced accumulation of ROS and partially reversed ATRA-induced apoptosis. These results support a role for topo IIbeta in survival of ATRA-differentiated myeloid leukemia cells. Reduced expression of topo IIbeta induces apoptosis in part by impairing the anti-oxidant capacity of the cell owing to downregulation of PRDX2. Thus, suppression of topo IIbeta and/or PRDX2 levels in myeloid leukemia cells provides a novel approach for improving ATRA-based differentiation therapy. | lld:pubmed |
| pubmed-article:16932348 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16932348 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16932348 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16932348 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16932348 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:HillJ EJE | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:WangJJ | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:BukowskiR MRM | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:ChikamoriKK | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:YenAA | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:GudkovA VAV | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:GanapathiRR | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:TanimotoMM | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:GanapathiM... | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:GrabowskiD... | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:ZarkhinEE | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:GrozavA GAG | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:VaziriS A JSA | lld:pubmed |
| pubmed-article:16932348 | pubmed:author | pubmed-author:RybickiL RLR | lld:pubmed |
| pubmed-article:16932348 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16932348 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:16932348 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16932348 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16932348 | pubmed:pagination | 1809-18 | lld:pubmed |
| pubmed-article:16932348 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:meshHeading | pubmed-meshheading:16932348... | lld:pubmed |
| pubmed-article:16932348 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16932348 | pubmed:articleTitle | Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest. | lld:pubmed |
| pubmed-article:16932348 | pubmed:affiliation | Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. | lld:pubmed |
| pubmed-article:16932348 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16932348 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16932348 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:7155 | entrezgene:pubmed | pubmed-article:16932348 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:16932348 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16932348 | lld:pubmed |
